Most drug programs don't fail at discovery. They fail at translation — because the biology tested against was never the biology that matters.
Unobio closes that gap.
We identify, license, and develop drug assets using AI-driven landscape mapping paired with patient-derived translational biology. Every candidate we advance is pressure-tested against human biology before IND — not after.
Demonstrated 94% concordance between in-silico predictions and observed translational outcomes.
We partner with pharma and biotech on asset licensing and co-development.
We find the drugs worth advancing.
→ unobio.com/licensing-pipeline

Unobio

Org chart

Teams

Offices

Unobio

Org chart

Teams

Offices

Related companies